Thermo Fisher Scientific (TMO) Short term Debt (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Short term Debt for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt rose 52.12% year-over-year to $3.4 billion; the trailing twelve-month figure through Jun 2026 stood at $3.4 billion (up 52.12% YoY), and the FY2025 full-year result was $3.5 billion, up 59.58% from the prior year.
• Short term Debt rose to $3.4 billion in Q2 2026 per TMO's latest filing, from $3.1 billion in the prior quarter.
• Across five years, Short term Debt topped out at $6.1 billion in Q2 2023 and bottomed at $1.0 billion in Q3 2022.
• Historically, Short term Debt has averaged $3.5 billion across 5 years, with a median of $3.6 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Short term Debt surged 46550.0% in 2022, then plunged 56.77% in 2025.
• Over 5 years, Short term Debt stood at $5.6 billion in 2022, then sank by 35.31% to $3.6 billion in 2023, then plunged by 38.65% to $2.2 billion in 2024, then surged by 59.58% to $3.5 billion in 2025, then declined by 4.67% to $3.4 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $3.4 billion, $3.1 billion, and $3.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.